Your browser doesn't support javascript.
loading
Efficacy of ALK5 inhibition in myelofibrosis.
Yue, Lanzhu; Bartenstein, Matthias; Zhao, Wanke; Ho, Wanting Tina; Han, Ying; Murdun, Cem; Mailloux, Adam W; Zhang, Ling; Wang, Xuefeng; Budhathoki, Anjali; Pradhan, Kith; Rapaport, Franck; Wang, Huaquan; Shao, Zonghong; Ren, Xiubao; Steidl, Ulrich; Levine, Ross L; Zhao, Zhizhuang Joe; Verma, Amit; Epling-Burnette, Pearlie K.
Afiliação
  • Yue L; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Bartenstein M; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
  • Zhao W; Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
  • Ho WT; Department of Pathology, Peggy and Stephenson Cancer Center, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • Han Y; Department of Pathology, Peggy and Stephenson Cancer Center, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • Murdun C; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Mailloux AW; Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, PR China.
  • Zhang L; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Wang X; Translational Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Budhathoki A; Department of Hematopathology and Laboratory Medicine.
  • Pradhan K; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
  • Rapaport F; Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
  • Wang H; Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
  • Shao Z; Leukemia Center, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Ren X; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
  • Steidl U; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
  • Levine RL; Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, PR China.
  • Zhao ZJ; Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
  • Verma A; Leukemia Center, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Epling-Burnette PK; Department of Pathology, Peggy and Stephenson Cancer Center, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA.
JCI Insight ; 2(7): e90932, 2017 04 06.
Article em En | MEDLINE | ID: mdl-28405618
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Quinolinas / Janus Quinase 2 / Fator de Crescimento Transformador beta1 / Receptores de Trombopoetina / Mielofibrose Primária / Receptor do Fator de Crescimento Transformador beta Tipo I Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Quinolinas / Janus Quinase 2 / Fator de Crescimento Transformador beta1 / Receptores de Trombopoetina / Mielofibrose Primária / Receptor do Fator de Crescimento Transformador beta Tipo I Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article